- Home
- ELDN vs JYNT Comparison
ELDN vs JYNT Comparison
Compare ELDN & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- JYNT
- Stock Information
- Founded
- ELDN 2004
- JYNT 2010
- Country
- ELDN United States
- JYNT United States
- Employees
- ELDN N/A
- JYNT N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- ELDN Health Care
- JYNT Miscellaneous
- Exchange
- ELDN Nasdaq
- JYNT Nasdaq
- Market Cap
- ELDN 178.4M
- JYNT 170.1M
- IPO Year
- ELDN N/A
- JYNT 2014
- Fundamental
- Price
- ELDN $2.68
- JYNT $11.42
- Analyst Decision
- ELDN Strong Buy
- JYNT Strong Buy
- Analyst Count
- ELDN 2
- JYNT 2
- Target Price
- ELDN $12.50
- JYNT $15.50
- AVG Volume (30 Days)
- ELDN 609.3K
- JYNT 87.8K
- Earning Date
- ELDN 08-18-2025
- JYNT 08-07-2025
- Dividend Yield
- ELDN N/A
- JYNT N/A
- EPS Growth
- ELDN N/A
- JYNT N/A
- EPS
- ELDN N/A
- JYNT N/A
- Revenue
- ELDN N/A
- JYNT $52,789,479.00
- Revenue This Year
- ELDN N/A
- JYNT $9.72
- Revenue Next Year
- ELDN N/A
- JYNT $10.92
- P/E Ratio
- ELDN N/A
- JYNT N/A
- Revenue Growth
- ELDN N/A
- JYNT 71.05
- 52 Week Low
- ELDN $2.30
- JYNT $9.58
- 52 Week High
- ELDN $5.54
- JYNT $15.32
- Technical
- Relative Strength Index (RSI)
- ELDN 38.39
- JYNT 51.64
- Support Level
- ELDN $2.60
- JYNT $10.85
- Resistance Level
- ELDN $2.91
- JYNT $13.00
- Average True Range (ATR)
- ELDN 0.17
- JYNT 0.87
- MACD
- ELDN -0.02
- JYNT -0.06
- Stochastic Oscillator
- ELDN 16.98
- JYNT 26.51
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.